@jmsadowska.bsky.social
a) Engineer b) Scientific communicator c) Pharma analyst d) All of the above My newsletter: https://joannasadowska.substack.com/subscribe
โก๏ธ Do you want to receive pharma updates like this one straight to your email?
๐ฉ Subscribe to my newsletter: buff.ly/4hHF1gM
โ Revenue of $54.1 billion (+18% Y/Y), driven by strong performance in oncology, cardiovascular, renal & metabolism (CVRM), and rare diseases.
โ AZ Lilly invested $13.6 billion in R&D, making up 25% of its revenue. They also invested 35% of their revenue in SG&A.
AstraZeneca released its FY24 financials, showing strong growth across its portfolio. Here's a quick breakdown of its performance.
โก๏ธ Do you want to receive pharma updates like this one straight to your email?
๐ฉ Subscribe to my newsletter: buff.ly/4hHF1gM
How much did pharma spend on sales in marketing in 2024?
SG&A (Selling, General, and Administrative) expenses in pharma cover the costs of running the business
These include marketing, sales, HR, legal fees, compliance costs, etc.
SG&A usually takes somewhere between 25-30% of the revenue
โก๏ธ Do you want to receive pharma updates like this one straight to your email?
๐ฉ Subscribe to my newsletter: http://buff.ly/4hHF1gM
โ GSK reported $39.8 billion in revenue, reflecting a 3% Y/Y growth.
โ Specialty medicines for HIV, respiratory, and immunology are a big part of their portfolio, generating over $11.8 billion in sales.
โ GSK invested $8.1 billion in R&D, making up 20% of its revenue.
GSK released its financial statements showing steady growth in revenue but significant cost increases impacting profitability.
Here is a breakdown of how the company performed in FY24
โก๏ธ Do you want to receive pharma updates like this one straight to your email?
๐ฉ Subscribe to my newsletter: buff.ly/4hHF1gM
Hereโs a quick breakdown of how Pfizer performed in FY24
โ Pfizer reported $63.9 billion in revenue (7% Y/Y growth).
โ Comirnaty still generated over $3.36 billion in sales.
โ Pfizer allocated $10.8 billion to R&D - this is 16.9% of their revenue.
โก๏ธ Do you want to receive pharma updates like this one straight to your email?
๐ฉ Subscribe to my newsletter: buff.ly/4hHF1gM
Revenue reflects not only profitability but also a companyโs strategy (e.g., investments in R&D, manufacturing, etc.) and healthcare market dynamics (e.g., oncology and immunology remain top therapeutic areas).
10.02.2025 13:00 โ ๐ 0 ๐ 0 ๐ฌ 1 ๐ 0
These 13 big pharma companies have generated a total revenue of almost 700 billion USD!
The financial reporting season is ongoing, and most pharma companies have now released their unaudited reports.
The pharma sector has shown year-on-year revenue growth, and 2024 is no exception.
โก๏ธ Do you want to receive pharma updates like this one straight to your email?
๐ฉ Subscribe to my newsletter: buff.ly/4hHF1gM
โ Lilly reported $45.0 billion in revenue, reflecting a 32% Y/Y growth.
โ Diabetes and obesity are becoming significant contributors to Eli Lilly's portfolio - Mounjaro generated $11.5 billion, Zepbound - $4.9B.
โ Lilly invested $11.0 billion in R&D, making up 24% of its revenue.
Eli Lilly and Company is another diabetes/obesity giant that released its financials from 2024 (unaudited).
Hereโs a quick breakdown of how the company performed in FY24.
โก๏ธ Do you want to receive pharma updates like this one straight to your email?
๐ฉ Subscribe to my newsletter: https://buff.ly/4hHF1gM
โ AbbVie reported USD 56.3 billion (+4% Y/Y) in net sales.
โ Immunology (USD 26.7B), neuroscience (USD 9.0B) and oncology (USD 6.6B) dominated their portfolio.
โ AbbVie invested USD 12.8B (22.7% of revenue) into research and development (R&D).
AbbVie reported their financial performance on January 31st. Here is the recap from their interim financial report.
03.02.2025 13:00 โ ๐ 2 ๐ 0 ๐ฌ 1 ๐ 1
NBC News recently highlighted the case of Wedam, who underwent the treatment at Children's National Hospital in Washington, D.C.
Here is the link: https://buff.ly/3EqAeBK
#cgt #biotech #pharma #drjojo
๐๐๐ง๐ ๐ญ๐ก๐๐ซ๐๐ฉ๐ข๐๐ฌ ๐๐จ๐ซ ๐ฌ๐ข๐๐ค๐ฅ๐ ๐๐๐ฅ๐ฅ ๐๐ข๐ฌ๐๐๐ฌ๐ ๐๐ซ๐ ๐๐ข๐ง๐๐ฅ๐ฅ๐ฒ ๐ซ๐๐๐๐ก๐ข๐ง๐ ๐ฉ๐๐ญ๐ข๐๐ง๐ญ๐ฌ
In 2023, two gene therapies were approved for SCD, but only a few patients have accessed them so far.
These therapies are finally reaching patients.
This brings a total of 43 CGT in the US market and 20 ATMPs in the European market.
๐๐ฉ๐ข๐ต ๐ข๐ฑ๐ฑ๐ณ๐ฐ๐ท๐ข๐ญ๐ด ๐ข๐ฏ ๐ธ๐ฆ ๐ฆ๐น๐ฑ๐ฆ๐ค๐ต ๐ช๐ฏ 2025?
#genetherapy #pharma #biotech #drjojo
*These include cell therapies, gene therapies or tissue engineering products
๐๐ก๐๐ญ ๐๐๐ฅ๐ฅ ๐๐ง๐ ๐ ๐๐ง๐ ๐ญ๐ก๐๐ซ๐๐ฉ๐ข๐๐ฌ ๐๐ซ๐ ๐๐ฉ๐ฉ๐ซ๐จ๐ฏ๐๐ ๐ข๐ง ๐ญ๐ก๐ ๐๐ ๐๐ง๐ ๐๐ฎ๐ซ๐จ๐ฉ๐?
2024 is over. This has been a good year for cell and gene therapies, especially in the US market, where 9 new CGT products* were approved.
In previous years, pharma companies would simply increase prices to offset losses. Thankfully, this strategy is no longer valid due to the Inflation Reduction Act passed under the Biden Administration.
๐๐ฐ๐ธ ๐ธ๐ช๐ญ๐ญ ๐ฑ๐ฉ๐ข๐ณ๐ฎ๐ข ๐ค๐ฐ๐ฎ๐ฑ๐ฆ๐ฏ๐ด๐ข๐ต๐ฆ ๐ง๐ฐ๐ณ ๐ต๐ฉ๐ฆ๐ด๐ฆ ๐ญ๐ฐ๐ด๐ด๐ฆ๐ด?
This is not the first time we have faced a patent cliff, but this one feels different.
Firstly, more biologics will face loss of exclusivity (LoE) this time, with biosimilars adding to the pressure by offering more affordable solutions.
๐๐จ๐ฐ ๐ฐ๐ข๐ฅ๐ฅ ๐ญ๐ก๐ ๐ฉ๐๐ญ๐๐ง๐ญ ๐๐ฅ๐ข๐๐ ๐ข๐ง ๐ฉ๐ก๐๐ซ๐ฆ๐ ๐ข๐ฆ๐ฉ๐๐๐ญ ๐ซ๐๐ฏ๐๐ง๐ฎ๐?
The patent cliff is approaching fast, with drugs representing $350 billion in annual worldwide revenues set to lose their exclusivity by 2030. The top 20 pharma companies account for 80% of this revenue loss.
โ J&J invested $17.3 billion (19.4% of revenue) into research and development (R&D).
Over the coming weeks, Iโll analyse the income statements of other pharma companies.
โก๏ธ Follow me if you donโt want to miss these updates.
#pharma #bioech #buesiness #drjojo
Key highlights:
โ J&J reported $88.8 billion total revenue, up 4% year-on-year (YoY), driven by pharmaceuticals ($57 billion) and medical devices ($31.9 billion).
โ Oncology ($20.8 billion) and immunology ($17.8 billion) segments dominate its pharmaceutical portfolio.
๐๐จ๐ฐ ๐๐จ๐ก๐ง๐ฌ๐จ๐ง & ๐๐จ๐ก๐ง๐ฌ๐จ๐ง ๐๐๐ซ๐ง๐๐ ๐๐ง๐ ๐ฌ๐ฉ๐๐ง๐ญ ๐ฆ๐จ๐ง๐๐ฒ ๐ข๐ง 2024?
Pharmaceutical companies have started releasing their financial statements for 2024. One of the first to do so is Johnson & Johnson, which announced its results earlier this week.
Here is the graphic of their FY24 Income Statement
